211 filings
Page 2 of 11
424B3
COEP
Coeptis Therapeutics Holdings Inc
15 Dec 23
Prospectus supplement
6:12pm
4
COEP
Coeptis Therapeutics Holdings Inc
11 Dec 23
Coeptis Therapeutics / David Mehalick ownership change
4:01pm
8-K
COEP
Coeptis Therapeutics Holdings Inc
5 Dec 23
Regulation FD Disclosure
4:30pm
424B3
COEP
Coeptis Therapeutics Holdings Inc
30 Nov 23
Prospectus supplement
5:00pm
EFFECT
COEP
Coeptis Therapeutics Holdings Inc
30 Nov 23
Notice of effectiveness
12:15am
CORRESP
COEP
Coeptis Therapeutics Holdings Inc
28 Nov 23
Correspondence with SEC
12:00am
UPLOAD
COEP
Coeptis Therapeutics Holdings Inc
22 Nov 23
Letter from SEC
12:00am
DEF 14A
COEP
Coeptis Therapeutics Holdings Inc
Definitive proxy
17 Nov 23
4:01pm
S-1
COEP
Coeptis Therapeutics Holdings Inc
IPO registration
15 Nov 23
12:00am
PRE 14A
COEP
Coeptis Therapeutics Holdings Inc
Preliminary proxy
7 Nov 23
4:45pm
D
COEP
Coeptis Therapeutics Holdings Inc
3 Nov 23
$2.00 mm in equity, sold $2.00 mm, 1 investor
2:03pm
8-K
COEP
Coeptis Therapeutics Holdings Inc
27 Oct 23
Coeptis Therapeutics Announces $2 Million Private Placement
4:01pm
8-K
COEP
Coeptis Therapeutics Holdings Inc
12 Oct 23
Unregistered Sales of Equity Securities
6:46pm
424B3
COEP
Coeptis Therapeutics Holdings Inc
26 Sep 23
Prospectus supplement
4:01pm
4
Chris Calise
31 Aug 23
Coeptis Therapeutics / Chris Calise ownership change
4:01pm
8-K
COEP
Coeptis Therapeutics Holdings Inc
30 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
4
Salkind Gene
30 Aug 23
Coeptis Therapeutics / Gene Salkind ownership change
3:15pm
8-K
COEP
Coeptis Therapeutics Holdings Inc
22 Aug 23
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
4:01pm
10-Q
2023 Q2
COEP
Coeptis Therapeutics Holdings Inc
Quarterly report
11 Aug 23
5:21pm